Although several recent studies have attempted to describe the association between psoriasis and migraine, there is little data in this regard. To explore the relationship between migraine and psoriasis. A total of 312 patients with psoriasis and 312 age- and gender-matched controls without psoriasis were recruited in this case-control study. Based on the diagnosis of migraine, they were divided into 4 subgroups: psoriasis with (PM+) and without (PM-) migraine, and control with (CM+) and without migraine (CM-). The subgroups were compared regarding the migraine and psoriasis characteristics. The mean (SD) age of patients and controls (139 males, in each group) was 43.2 (13.2) years. Psoriasis patients were significantly more likely to have migraine (OR = 2.789). Migraine with aura was significantly higher in the PM + group than in the CM + group (p = 0.007). The mean PASI score (p = 0.001), frequency of moderate and severe psoriasis (p = 0.048), and frequency of patients with PsA (p < 0.001) were significantly higher in PM + compared to PM-. The risk of migraine substantially increased with increasing psoriasis severity (OR = 2.062, OR = 3.248, and OR = 4.586 for mild, moderate, and severe, respectively), and with the presence of PsA (OR = 2.438 and OR = 12.930 for patients without and with PsA, respectively). Observational nature, not including all confounding factors, not addressing a cause-and-effect relationship. In comparison with the non-psoriatic control group, psoriasis patients are predisposed to a significantly higher risk of migraine, particularly migraine with aura, psoriasis patients with more severe disease and those with PsA have a markedly higher risk of having migraine, and the migraine headache index is significantly higher in psoriasis patients.

Background: Weaning of ventilated COVID-19 patients from ventilators has been a major problem in some of these patients. We performed hemoperfusion in a selective group of COVID-19 patients to facilitate weaning from the mechanical ventilation (MV). Methodology: The present study was a retrospective case series of 30 consecutive COVID-19 patients, who showed difficulty with weaning off the ventilator. Hemoperfusion was performed by the HA330 disposable hemoperfusion cartridge (Jafron, China). Before and after hemoperfusion, changes in patients' hemodynamics, improvement in consciousness level, oxygen saturation, hypercapnia, initiating spontaneous breathing, and changes in lung involvement were assessed. Results: The patients average age was 48.38 ± 15.04 years, with 17 (56.7%) females. The post-hemoperfusion values of SpO2 (P < 0.001), mean arterial pressure (P = 0.003), positive end-expiratory pressure (P < 0.001), heart rate (P < 0.001), and ratio of arterial oxygen partial pressure to fractional inspired oxygen (P < 0.001) were significantly different compared to their pre-hemoperfusion values. The outcome of patients showed a significant relationship with age (P = 0.017) and spontaneous ventilation (P = 0.001). Conclusions: The findings endorse the implementation of hemoperfusion for ICU-hospitalized COVID-19 patients experiencing difficulty in weaning from mechanical ventilation. Hemoperfusion demonstrated significant improvements in vital signs for the majority of patients and was associated with a successful weaning and survival rate of 63.3%. While these results are promising, further evidence is needed to consider hemoperfusion as an accepted clinical approach.